Cargando…
Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
BACKGROUND: Hereditary angioedema (HAE), a rare disease that is characterized by painful and recurring non‐allergic swelling episodes, is caused by the deficiency or dysfunction of C1 inhibitor (C1INH) protein. A comprehensive HAE management plan may require long‐term prophylaxis (LTP) in addition t...
Autores principales: | Anderson, John, Maina, Njeri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764638/ https://www.ncbi.nlm.nih.gov/pubmed/35079346 http://dx.doi.org/10.1002/clt2.12092 |
Ejemplares similares
-
Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021) -
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019) -
Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014) -
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017) -
Short-term Prophylaxis for Delivery in Pregnant Women with Hereditary Angioedema with Normal C1-Inhibitor
por: Moraes, Caroline Guth de Freitas Batista de, et al.
Publicado: (2020)